<span item_type="fundamental" item_id="26104231c1bfdfca26d2b791f6d3d0ea" counter_id="ST/US/BOWN" env="prod"></span><span item_type="announcement" item_id="549810883773667074" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD 0.22.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any operating revenues as of June 30, 2025, as it is still in the process of identifying a target for its initial business combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1973056/000164117225024385/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>For the three months ended June 30, 2025, the company reported a net income of $750,303, compared to a net income of $816,754 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1973056/000164117225024385/form10-q.htm"></span></li><li>For the six months ended June 30, 2025, the company reported a net loss of - $1,289,691, compared to a net income of $1,603,116 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1973056/000164117225024385/form10-q.htm"></span></li><li>Operating costs for the three months ended June 30, 2025, were $76,828, and for the six months ended June 30, 2025, were $211,563.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1973056/000164117225024385/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the six months ended June 30, 2025, was - $86,218.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1973056/000164117225024385/form10-q.htm"></span></li><li>Cash and cash equivalents as of June 30, 2025, were $17,556, down from $103,774 as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1973056/000164117225024385/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company recorded a loss on issuance of FPA liability of - $1,929,656 and a gain from the change in fair value of FPA liability of $1,123,154 for the six months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1973056/000164117225024385/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is focused on completing its initial business combination, with a proposed merger involving Shenzhen Qianzhi BioTechnology Co. Ltd. The company has extended the deadline for completing this business combination to December 14, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1973056/000164117225024385/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company has entered into a Prepaid Forward Purchase Agreement to manage share redemptions and maintain liquidity during the business combination process.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1973056/000164117225024385/form10-q.htm"></span></li><li><strong>Priority</strong>: The company is prioritizing the completion of its business combination within the extended timeframe to avoid liquidation and dissolution.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1973056/000164117225024385/form10-q.htm"></span></li></ul>

Bowen Acquisition | 10-Q: FY2025 Q2 EPS: USD 0.22